• Explore /
  • Poster
  • / <span>DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1</span>.

DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.

Abstract Poster

Authors

Martin Voss

Martin Henner Voss

Memorial Sloan Kettering Cancer Center, New York, NY

Martin Henner Voss , Elizabeth R. Plimack , Brian I. Rini , Michael B. Atkins , Robert Alter , Rupal Satish Bhatt , J. Thaddeus Beck , Kristen M. Pappas , Dawn Wilson , Xiaosha Zhang , Matthew L. Sherman , Shuchi Sumant Pandya

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT01727336

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 407)

DOI

10.1200/jco.2015.33.7_suppl.407

Abstract #

407

Poster Bd #

B5

Abstract Disclosures

Similar Posters

First Author: Martin Henner Voss

First Author: Michael B. Atkins

First Author: Martin Henner Voss

First Author: Yousef Zakharia